PMID- 36530912
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221222
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 9
DP  - 2022
TI  - Characteristics of dust mite sublingual immunotherapy-associated adverse events 
      in the early phase.
PG  - 1015032
LID - 10.3389/fmed.2022.1015032 [doi]
LID - 1015032
AB  - BACKGROUND: Few studies reported the characteristics of house dust mite (HDM) 
      sublingual immunotherapy (SLIT) adverse events (AEs) during early phase 
      treatment. The aim of this prospective study was mainly to explore the 
      characteristics of AEs in allergic rhinitis (AR) patients during 6 months of HDM 
      SLIT. METHODS: A total of 242 patients with AR were enrolled in this study. 
      Telephone follow-up and administration were conducted in the every week of the 
      first month, the third month, and the sixth month of SLIT treatment. Furthermore, 
      the early efficacy, AEs, and compliance were analyzed in our study. RESULTS: 
      Overall, 70.25% (170/242) of the AR patients completed the study, while 29.75% 
      (72/242) of the AR patients failed to complete the whole 6 months of SLIT 
      treatment process. On the whole, symptoms improved in 87.65% (149/170) of 
      patients including 34.12% (58/170) well-controlled and 53.53% (91/170) partially 
      controlled. The correlation analysis results showed that the treatment effect was 
      negatively correlated with the age (r = -0.1614, P = 0.0355). The AEs mainly 
      occurred in the first month, comprised of local rashes, gastrointestinal 
      reactions, and itching of mouth and tongue. Subgroup analysis in the first month 
      showed the itching of mouth and tongue, gastrointestinal reactions, fatigue, and 
      other AEs in >/=14 years old group (14-65 years old, n = 42) were significant 
      differences when compared with that in the <14 years old group (4-13 years old, n 
      = 128, all P < 0.05). In the study, the main reasons for terminated immunotherapy 
      were drug inaccessibility, loss of follow-up and long course of treatment. 
      CONCLUSION: Patients with AR who received HDM SLIT revealed an early efficacy 
      after 6 months, with AEs mostly occurred in the first month.
CI  - Copyright (c) 2022 Chen, Lin, Yan, Xu and Chai.
FAU - Chen, Ming
AU  - Chen M
AD  - Department of Otolaryngology, The Second Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou, China.
FAU - Lin, Lin
AU  - Lin L
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Huashan Hospital of 
      Fudan University, Shanghai, China.
FAU - Yan, Maoxiao
AU  - Yan M
AD  - Department of Otolaryngology, The Second Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou, China.
FAU - Xu, Chong
AU  - Xu C
AD  - Department of Respiration and Anaphylaxis Treatment Center, General Hospital of 
      North Theater Command, Shenyang, Liaoning, China.
FAU - Chai, Ruonan
AU  - Chai R
AD  - Department of Respiration and Anaphylaxis Treatment Center, General Hospital of 
      North Theater Command, Shenyang, Liaoning, China.
LA  - eng
PT  - Journal Article
DEP - 20221202
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC9755350
OTO - NOTNLM
OT  - adverse events
OT  - allergic rhinitis
OT  - early efficacy
OT  - house dust mite
OT  - sublingual immunotherapy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/12/20 06:00
MHDA- 2022/12/20 06:01
PMCR- 2022/12/02
CRDT- 2022/12/19 03:39
PHST- 2022/08/09 00:00 [received]
PHST- 2022/11/21 00:00 [accepted]
PHST- 2022/12/19 03:39 [entrez]
PHST- 2022/12/20 06:00 [pubmed]
PHST- 2022/12/20 06:01 [medline]
PHST- 2022/12/02 00:00 [pmc-release]
AID - 10.3389/fmed.2022.1015032 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2022 Dec 2;9:1015032. doi: 10.3389/fmed.2022.1015032. 
      eCollection 2022.